Answers are grounded in this paper and cite their sources.
// Yun Cui 1, * , Fuming Zhang 2, * , Chunkai Zhu 2 , Liang Geng 1 , Tongde Tian 1 , Huaimin Liu 1 1 Department of Integrated Chinese and Western Medicine, Henan Provincial Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, China 2 Clinical Laboratory, People’s Hospital of Zhengzhou University, Henan Provincial People’s Hospital, Zhengzhou, Henan, 450008, China * These authors contributed equally to this work Correspondence to: Huaimin Liu, email: huaiminliu_doc007@163.com Keywords: non-small cell lung cancer, LncRNA SNHG1, miR-101-3p, SOX9, Wnt/β-catenin signaling pathway Received: November 30, 2016 Accepted: January 11, 2017 Published: January 27, 2017 ABSTRACT Lung cancer is the most common and aggressive tumor in the world. Long non-coding RNA small nucleolar RNA host gene 1 (lncRNA SNHG1) play critical roles in the progression of cancers. However, the function and underlying mechanism remain unclear in lung cancer. In the current study, we found that expression of SNHG1 was up-regulated in non-small cell lung cancer (NSCLC) tissues and cell lines. NSCLC patients with high SNHG1 expression were significantly correlated with larger tumor size, advanced TNM stage, lymph node metastasis and poor overall survival than patients with low SNHG1 expression. Furthermore, function assays showed that SNHG1 inhibition suppressed NSCLC cell proliferation both in vitro and in vivo . We also found that miR-101-3p could act as a target of SNHG1 in NSCLC and the inhibition of NSCLC progression induced by SNHG1 knockdown required the activity of miR-101-3p. In addition, we identified that SOX9 acted as a target of miR-101-3p, and SOX9 played the oncogenic role in NSCLC by activating Wnt/β-catenin signaling pathway. Taken together, our study suggested that lncRNA SNHG1 could promote NSCLC progression via miR-101-3p and SOX9. The SNHG1/miR-101-3p/SOX9/Wnt/β-catenin axis regulatory network might provide a potential new therapeutic strategy for lung cancer treatment.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: